Spyryx Biosciences is Pharmaceuticals in United States that focus on Obstructive Pulmonary Disorder business. Founded in 2013. They cover business area such as operator, innovative therapeutic, severe lung disease, inhale peptide, severe pulmonary disease, mucus accumulation, obstruction, disease progression, healthcare institute, orphan lung, respiratory disease, Cystic Fibrosis, Chronic Obstructive Pulmonary Disorder.
2013
( 11 years old in 2024 )
Obstructive Pulmonary Disorder
-
801-10 Capitola Drive
Durham, NC 27713
United States
Private
operatorinnovative therapeuticsevere lung diseaseinhale peptidesevere pulmonary diseasemucus accumulationobstructiondisease progressionhealthcare instituteorphan lungrespiratory diseaseCystic FibrosisChronic Obstructive Pulmonary Disorder
* We use standard office opening hours in near Spyryx Biosciences's location as default value for unknown and outdated data. For more valid info, please verify the info from more trusted sources like GoogleMyBusiness, Yelp, FourSquare or similar services.
Spyryx Biosciences is Pharmaceuticals business from United States that founded in 2013 (11 years old in 2024), Spyryx Biosciences business is focusing on Obstructive Pulmonary Disorder.
Spyryx Biosciences headquarter office and corporate office address is located in 801-10 Capitola Drive Durham, NC 27713 United States.
Spyryx Biosciences was founded in United States.
In 2024, Spyryx Biosciences is currently focus on Obstructive Pulmonary Disorder sector.
Above is snippet of Google Trends for "Obstructive Pulmonary Disorder" term, if you have problem loading the snippet, please visit here: Google Trend.
Disclaimer: This website is not affiliated with Spyryx Biosciences, any government agency, does not create this data, vouch for its accuracy, or guarantee that it is the most recent data available. The data displayed is available through open government websites and public online directory. This website expressly disclaims the accuracy, adequacy, or completeness of any data and shall not be liable for any errors, omissions or other defects in, delays or interruptions in such data, or for any actions taken in reliance thereon.
